In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Effects of Tumor Treating Fields (TTFields) on Health-Related Quality of life (HRQoL) in Newly Diagnosed Glioblastoma: An Exploratory Analysis of the EF-14 Randomized Phase III Trial

    Final Number:
    1268

    Authors:
    Steven A. Toms MD MPH FAANS FACS; Zvi Ram MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2018 Annual Meeting

    Introduction: TTFields are a novel treatment modality that continuously delivers alternating electric fields to the tumor region. TTFields interfere with the assembly of the mitotic spindle leading to apoptosis. In the EF-14 phase III study in newly diagnosed glioblastoma, TTFields plus temozolomide (TTFields/TMZ) showed significant increase in overall and 5-year survival rates compared to temozolomide. TTFields/TMZ did not negatively impact nine prespecified HRQoL scales (global health, physical, cognitive, role, social and emotional functioning, itchy skin, pain, and leg weakness) except for increased itchy skin. We present an exploratory analysis of the remaining 17 EORTC QLQ C-30 and BN-20 HRQoL scales.

    Methods: HRQoL was measured by the EORTC QLQ-C30 and BN20 questionnaires at baseline and every 3 months thereafter. Mean changes from baseline as well as significant changes in scores over time (>10 points) were evaluated using a repeated measures test. Deterioration-free survival and time-to-deterioration in HRQoL were assessed for each scale, as well as % patients with stable/improved HRQoL versus baseline.

    Results: No statistically or clinically significant decline in any of the exploratory HRQoL scales was seen in the repeated measures analysis or in time to deterioration. Significantly more patients treated with TTFields/TMZ versus TMZ reported stable/improved bladder control (63.6% versus 46.8%, p=0.001) and diarrhea (60.6% versus 43.7%, p=0.001) compared to baseline. The deterioration-free survival for diarrhea, future uncertainty and headaches was significantly delayed in TTFields/TMZ treated patients compared to TMZ alone (HR 0.68, 0.71 and 0.67, respectively, p<0.001).

    Conclusions: The delay in deterioration-free survival and increase in %patients with stable/improved HRQoL in several additional HRQoL scales may be attributed in part to the longer progression-free survival observed in TTFields/TMZ treated patients in the EF-14 trial. No negative impact of HRQoL was seen in any of the exploratory scales. These results support adding TTFields to standard therapy in newly diagnosed glioblastoma.

    Patient Care: This data will show that tumor treating fields improves health related quality of life and delays deterioration of quality of life in patients with glioblastoma.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of quality of life in treatment of glioblastoma with tumor treating fields, 2) Discuss, in small groups, the effect of tumor treating fields on health related quality of life, 3) Identify an effective treatment for glioblatoma.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy